title: [Treatment of various types of acute leukemia in adult. An analysis of 98 cases. The Leukemia Cooperation Group of Beijing City].
abstract: 47 cases of acute non-lymphocytic leukemia (ANLL) were treated with daunorubicin, cytosine arabinoside. Complete remission (CR) rate was 61.7%. 6 cases of ANLL M3 type were treated with trans-retinoic acid and all had CR. 45 cases of acute lymphocytic leukemia (ALL) were treated with vincristine, daunorubicin, cyclophosphamide, prednisone with a CR rate of 88.9%. The preliminary result of consolidation or intensive therapy after CR was reported. The toxic and side effects of all kinds of treatment program were described.
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone; D003630:Daunorubicin